Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients

PURPOSE: ERBB2 exon 20 insertions (20ins) have been identified as oncogenic drivers in lung cancers. Lung cancer patients with 20ins benefit from afatinib. However, response heterogeneity was observed in patients harboring different 20ins subtypes. In this study, we interrogated clinical characteris...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhefeng, Wu, Lin, Cao, Jun, Yang, Zhe, Zhou, Chengzhi, Cao, Liming, Wu, Hao, Shen, Haibo, Jin, Meiling, Zhang, Yong, Mao, Xinru, Xiang, Jianxing, Ma, Ke, Li, Bing, Zhang, Tengfei, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205822/
https://www.ncbi.nlm.nih.gov/pubmed/30425522
http://dx.doi.org/10.2147/OTT.S173391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205822/
https://www.ncbi.nlm.nih.gov/pubmed/30425522
http://dx.doi.org/10.2147/OTT.S173391

Ejemplares similares